Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heike Schwarb

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Therapeutische Umschau. Revue Therapeutique|March 12, 2020
[Chronic Lymphocytic Leukemia]Heike Schwarb, Dominik Heim
Dentistry Journal|March 23, 2018
New Direct Oral Anticoagulants (DOAC) and Their Use TodayHeike Schwarb, Dimitrios A Tsakiris
Therapeutische Umschau. Revue Therapeutique|January 4, 2017
Ramona Merki, Heike Schwarb, Dimitrios A Tsakiris
Therapeutische Umschau. Revue Therapeutique|March 12, 2020
[Myelodysplastic Syndromes]Gregor Stehle, Heike Schwarb, Jakob R Passweg
American Journal of Hematology|January 26, 2011
Bone marrow trephine biopsy findings in B acute lymphoblastic leukaemia of early precursor (Pro-B) subtypeHeike Schwarb, Philippa C May, Jane Apperley, et al.
International Journal of Cancer|November 13, 2009
Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosisInti Zlobec, Michel P Bihl, Heike Schwarb, et al.
European Journal of Haematology|November 1, 2012
Lymphodepletion chemotherapy followed by donor leukocytes for post-transplantation relapse of myelofibrosis after previous donor leukocyte infusion failureEmma Lucy Neave, Heike Schwarb, Abdurrazag Shlebak, et al.
Cancer|January 10, 2018
Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07)Michael Montemurro, Angela Cioffi, Julien Dômont, et al.
British Journal of Haematology|December 17, 2016
Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2<sup>nd</sup> -line therapy for relapsed and refractory multiple myeloma - a phase II trialUlrich J M Mey, Wolfram Brugger, Heike Schwarb, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Therapeutische Umschau. Revue Therapeutique|March 12, 2020
[Chronic Lymphocytic Leukemia]Heike Schwarb, Dominik Heim
Dentistry Journal|March 23, 2018
New Direct Oral Anticoagulants (DOAC) and Their Use TodayHeike Schwarb, Dimitrios A Tsakiris
Therapeutische Umschau. Revue Therapeutique|January 4, 2017
Ramona Merki, Heike Schwarb, Dimitrios A Tsakiris
Therapeutische Umschau. Revue Therapeutique|March 12, 2020
[Myelodysplastic Syndromes]Gregor Stehle, Heike Schwarb, Jakob R Passweg
American Journal of Hematology|January 26, 2011
Bone marrow trephine biopsy findings in B acute lymphoblastic leukaemia of early precursor (Pro-B) subtypeHeike Schwarb, Philippa C May, Jane Apperley, et al.
International Journal of Cancer|November 13, 2009
Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosisInti Zlobec, Michel P Bihl, Heike Schwarb, et al.
European Journal of Haematology|November 1, 2012
Lymphodepletion chemotherapy followed by donor leukocytes for post-transplantation relapse of myelofibrosis after previous donor leukocyte infusion failureEmma Lucy Neave, Heike Schwarb, Abdurrazag Shlebak, et al.
Cancer|January 10, 2018
Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07)Michael Montemurro, Angela Cioffi, Julien Dômont, et al.
British Journal of Haematology|December 17, 2016
Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2<sup>nd</sup> -line therapy for relapsed and refractory multiple myeloma - a phase II trialUlrich J M Mey, Wolfram Brugger, Heike Schwarb, et al.
Pageof 1